Dr. Hammers on the Future of Treatments for RCC

Hans J. Hammers, MD, PhD
Published: Thursday, Aug 10, 2017



Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the future of treatments for patients with renal cell carcinoma (RCC).

It is an exciting time in kidney cancer, explains Hammers. Ever since the approval of nivolumab (Opdivo), checkpoint inhibitors have continued to see excitement. However, the question remains to be: what is next for these treatments?

Nivolumab has shown durable response rates of around 20% but it is not enough to effectively treat patients with immunotherapy, states Hammers. Therefore, this has been looked at in combination with targeted agents, such as VEGF inhibitors.

SELECTED
LANGUAGE


Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the future of treatments for patients with renal cell carcinoma (RCC).

It is an exciting time in kidney cancer, explains Hammers. Ever since the approval of nivolumab (Opdivo), checkpoint inhibitors have continued to see excitement. However, the question remains to be: what is next for these treatments?

Nivolumab has shown durable response rates of around 20% but it is not enough to effectively treat patients with immunotherapy, states Hammers. Therefore, this has been looked at in combination with targeted agents, such as VEGF inhibitors.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x